Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trilaciclib + docetaxel
- Development stage
- Phase 2
- Lead developer
- G1 Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**Trilaciclib + docetaxel** is an investigational combination therapy currently being evaluated in clinical trials for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have failed at least one prior line of therapy. Trilaciclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor administered intravenously before docetaxel chemotherapy. Its primary purpose in this combination is to protect bone marrow from chemotherapy-induced myelosuppression by transiently arresting hematopoietic stem and progenitor cells in the G1 phase, thereby reducing the incidence and severity of toxicities like neutropenia and febrile neutropenia. Docetaxel is a taxane-class chemotherapeutic agent that inhibits microtubule depolymerization, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. The combination is being investigated in phase II studies for its efficacy in reducing hematologic toxicity and improving outcomes in NSCLC[1][3][5].
- Other names
- trilaciclib + docetaxel
02
Targets
CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)SLC47A1 (Multidrug and toxin extrusion transporter 1)MATE2-K (Multidrug and toxin extrusion protein 2)OCT2 (Organic cation transporter 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on trilaciclib + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trilaciclib + docetaxel.